T-bet or not T-bet
We depend on the efficiency of our adaptive immune system to combat pathogen invaders. Part of this protective response includes development of CD4 and CD8 effector T cells. As Hatton and Weaver discuss in their Perspective, key transcription factors regulating CD4 effector T cell development have been identified, whereas those governing the development of CD8 effectors have not. Hatton and Weaver describe new work showing that cooperation between two T-box transcription factors, T-bet and Eomesodermin, instigates the CD8 effector program.
By Robin D. Hatton and Casey T. Weaver.
[About AIDScience articles] [See recent AIDScience articles]
Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1-infected children in resource-poor settings
Cheaper, simpler alternatives to CD4 lymphocyte count and HIV-1 RNA detection for assessing the prognosis of HIV-1 infection are needed for resource-poor settings. Additional studies in HIV-1-infected children should be conducted to establish guidelines and locally appropriate thresholds to use these alternative assays in different settings. The Lancet 362, 1625-27, 15 November 2003. Free full-text article.
VaxGen announces results of its phase III HIV vaccine trial in Thailand: Vaccine fails to meet endpoints
The company announced preliminary results from its randomized, double-blind, placebo-controlled Phase III clinical trial in Thailand to evaluate AIDSVAX B/E, an investigational vaccine (rgp 120) for the prevention of HIV infection. The vaccine candidate did not show efficacy for either the primary or secondary endpoints.
M cell DNA vaccination for CTL immunity to HIV
Reovirus protein s1 was adapted to ferry DNA vaccines to the mucosa of mice to immunize against HIV, as protein s1-poly-L-lysine-DNA complexes. Mice vaccinated with a formulated gp160 DNA vaccine showed potent antiviral immunity against vaccinia virus-env replication in ovaries. The Journal of Immunology 171, 4717, 1 November 2003.